Ashling Mulvaney has been in the pharmaceutical industry for 20 years, and with AstraZeneca since 2008, in a range of access-focused roles across therapy areas including cardiovascular, diabetes and respiratory.
Ashling led the Global pricing and market access teams for the Cardiovascular Renal Metabolism (CVRM) portfolio and was the reimbursement expert for the acquisition of the diabetes portfolio from Bristol-Myers Squibb (BMS).
In 2016, Ashling took on leadership of AstraZeneca’s flagship Healthy Heart Africa (HHA) programme, active since 2014 tackling hypertension and cardiovascular disease across East and West Africa, as well as India.
In her current role as Head of Access to Healthcare, Global Sustainability, Ashling leads one of the three priority pillars of AstraZeneca’s sustainability strategy, working towards a future where all people have access to sustainable healthcare solutions for life-changing treatment and prevention.
She focuses on addressing the burden of non-communicable diseases in emerging economies, by working with stakeholders and in public-private partnerships to promote disease prevention, remove barriers to access, and strengthen health systems in support of local communities for greatest impact.
AstraZeneca’s access programmes had reached more than 19.8m people and trained more than 81,000 healthcare workers by the end of 2019. In April 2020, Ashling took on the role of Co-Chair of Private Sector Roundtable (PSRT), part of the Global Health Security Agenda (GHSA), which highlights the critical role that the private sector plays in responding to global health challenges and emergencies.